Literature DB >> 1587406

Primary sclerosing cholangitis in ulcerative colitis--a risk factor for the development of dysplasia and DNA aneuploidy?

U Broomé1, G Lindberg, R Löfberg.   

Abstract

In a 15-year surveillance program for long-standing, total ulcerative colitis (UC), 72 patients were followed up with colonoscopic biopsies. Seventeen patients developed definite dysplasia, carcinoma, and/or DNA aneuploidy. Alkaline phosphatase and transaminases were examined in all patients. In the group with dysplasia, carcinoma, and/or DNA aneuploidy, 5 patients (28%) were found to have primary sclerosing cholangitis (PSC) based on histological and/or cholangiographic criteria. In the group without definite dysplasia or DNA aneuploidy, no patient with PSC appeared, although two patients with other forms of chronic liver disorders were found. The difference in distribution of PSC between the two groups was statistically significant (P = 0.0004). Using logistic regression, the presence of PSC and the duration of UC were identified as independent risk factors associated with dysplasia and/or DNA aneuploidy. Thus, UC patients with PSC seem to run an increased risk of developing colonic dysplasia and/or DNA aneuploidy. Although the reason for the increased risk is still unclear, these results warrant increased surveillance among patients with both PSC and longstanding, total UC.

Entities:  

Mesh:

Year:  1992        PMID: 1587406     DOI: 10.1016/0016-5085(92)90308-l

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  26 in total

Review 1.  Current therapies and clinical controversies in the management of primary sclerosing cholangitis.

Authors:  R T Prall; K D Lindor; R H Wiesner; N F LaRusso
Journal:  Curr Gastroenterol Rep       Date:  2000-04

2.  Hepatic and extrahepatic malignancies and primary sclerosing cholangitis.

Authors:  E Schrumpf; K M Boberg
Journal:  Gut       Date:  2003-02       Impact factor: 23.059

3.  Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease.

Authors:  J A Eaden; J F Mayberry
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

Review 4.  The approach to dysplasia surveillance in inflammatory bowel disease.

Authors:  Remo Panaccione
Journal:  Can J Gastroenterol       Date:  2006-04       Impact factor: 3.522

Review 5.  Inflammatory bowel disease: the problems of dysplasia and surveillance.

Authors:  P J Mitchell; E Salmo; N Y Haboubi
Journal:  Tech Coloproctol       Date:  2007-11-30       Impact factor: 3.781

Review 6.  Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies.

Authors:  Peter-Laszlo Lakatos; Laszlo Lakatos
Journal:  World J Gastroenterol       Date:  2008-07-07       Impact factor: 5.742

7.  PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis.

Authors:  E V Loftus; G C Harewood; C G Loftus; W J Tremaine; W S Harmsen; A R Zinsmeister; D A Jewell; W J Sandborn
Journal:  Gut       Date:  2005-01       Impact factor: 23.059

Review 8.  Has the risk of colorectal cancer in inflammatory bowel disease decreased?

Authors:  Nynne Nyboe Andersen; Tine Jess
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

9.  Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis.

Authors:  Harry Sokol; Jacques Cosnes; Olivier Chazouilleres; Laurent Beaugerie; Emmanuel Tiret; Raoul Poupon; Philippe Seksik
Journal:  World J Gastroenterol       Date:  2008-06-14       Impact factor: 5.742

Review 10.  Management of ulcerative colitis pre- and post-liver transplant for primary sclerosing cholangitis: two case reports and review of literature.

Authors:  Kiranpreet Khosa; Kofi Clarke
Journal:  Int J Colorectal Dis       Date:  2014-07-04       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.